Pixium Vision (PIX) - Building feasibility data on way to pivotal study

09:09 EDT 28 Oct 2019 | Edison Investment Research

Edison Investment Research - Pharmaceuticals & healthcare - Pixium Vision: Patients in the ongoing, five-patient European feasibility trial on Prima are starting to use the second-generation Prima 2 glasses, which may further enhance the visual experience of patients implanted with the current 378-electrode Prima chip. Initial implantations for the US feasibility study are anticipated shortly. Data accumulated from these studies should help inform the pivotal study programme, expected to start in mid-2020. We obtain an equity valuation of €78m (vs €76m previously).
ISIN: FR0011950641

Original Article: Pixium Vision (PIX) - Building feasibility data on way to pivotal study


More From BioPortfolio on "Pixium Vision (PIX) - Building feasibility data on way to pivotal study"

Quick Search

Relevant Topics

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...